Our Science
Tinker's proprietary FORGE platform, leveraging cross-species translational screening, unlocks unparalleled design and optimization of multimeric ASO and siRNA constructs with tunable linkers in dimer, trimer, and tetramer configurations. Monomers are individually modified with a novel conjugate and proprietary chemical modification patterns for superior CNS distribution and durable knockdown which outperforms current best-in-class technology for siRNA-mediated knockdown in all brain regions. This delivers a multi-targeting configuration through a single chemical entity for simultaneous silencing, up-regulation, or precise combinatorial knockdown with finely tuned polypharmacology aligned with disease-specific synergistic gene networks for combinatorial efficacy.
Introducing
The FORGE Platform
%20(2).jpg)
FORGE: Fused Oligonucleotides for Regulation of Gene Expression
Tinker Therapeutics has protected and wholly owns its fundamental trade secrets, methods, architectures, and know-how related to its platform, called Fused Oligonucleotides for Regulation of Gene Expression (“FORGE”). FORGE delivers a novel development toolkit for the design of cleavable multimeric oligonucleotide constructs.
How It Works
Our FORGE Platform Yields Multimeric Oligonucleotides with Optimized Linker Chemistries
01
Oligo Design
Optimized design of ASO/siRNA sequence, backbone chemistry, sugar modifications, and proprietary conjugates
02
Proprietary Linker Chemistry
Tunable linkers
Linkers chemically optimized on a target-, sequence-, chemistry-, and indication-specific basis
03
FORGE Platform
Fused Oligonucleotides for Regulation of Gene Expression
Well-Suited for Complex, Polygenic Neurological Diseases
Novel chemical modifications and conjugation technology outperforms current best-in-class distribution technology for siRNA-mediated knockdown in all brain regions
Cross-Species Translational Screening
Target and off-target screening uses cross-species conserved sequences to ensure minimal hybridization- dependent off-target effects and pathology translation
Proprietary CNS-Conjugate Delivery Chemistry
Novel conjugates with proprietary chemical group for superior CNS distribution and durable knockdown
High Efficacy, Multi-Target Configuration
Novel MOA for simultaneous silencing. up-regulation, or precise combinatorial knockdown, and uptake in same cell
Tunable Cleavability for PK/PD
Cleavability enables controlled payload release after cellular internalization and optimal PK/PD
CNS Specific Polypharmacology
Finely tuned polypharmacology aligned with disease-specific synergistic gene networks, delivering combinatorial efficacy
Optimized for Intrathecal Delivery
Direct IT administration, ensuring durable exposure, broad parenchymal distribution, and translational feasibility with strong regulatory readiness precedent in CNS
FTO + Rapid Dev with Single Multimeric Agent
Single chemical entities composed of complex modular constructs enable unrestricted commercial development/IP FTO and fast-to-clinic development strategy